

TITULO	REVISTA	FI	Q/D	DOI	Pubmed Id	UT (Unique WOS ID)
An in vitro model for osteoarthritis using long-cultured inflammatory human macrophages repeatedly stimulated with TLR agonists	EUROPEAN JOURNAL OF IMMUNOLOGY	5,4	2	10.1002/eji.202350507	37713238	WOS:001079041400001
Synthetic peptides of IL-1Ra and HSP70 have anti-inflammatory activity on human primary monocytes and macrophages: Potential treatments for inflammatory diseases	NANOMEDICINE- NANOTECHNOLOGY BIOLOGY AND MEDICINE	5,4	2	10.1016/j.nano.2023.102719	37977510	WOS:001124151200001
Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma	MOLECULAR ONCOLOGY	6,6	1	10.1002/1878-0261.13506	37558206	WOS:001067471300001
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)	CLINICAL & TRANSLATIONAL ONCOLOGY	3,4	3	10.1007/s12094-023-03202-9	37133731	WOS:000980817100002
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)	CLINICAL & TRANSLATIONAL ONCOLOGY	3,4	3	10.1007/s12094-023-03216-3	37418123	WOS:001023961900001
Difficulties on the access to innovative targeted therapies for lung cancer in Spain	CLINICAL & TRANSLATIONAL ONCOLOGY	3,4	3	10.1007/s12094-023-03303-5	37651020	WOS:001062542500002
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial	ANNALS OF ONCOLOGY	50,5	D1	10.1016/j.annonc.2023.02.012	36863484	WOS:000990318500001
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1	ANNALS OF ONCOLOGY	50,5	D1	10.1016/j.annonc.2023.07.006	37704166	WOS:001086506500001
Locoregional relapse after sparing mastectomies and immediate reconstruction in women with breast cancer	CIRUGIA ESPANOLA	1,9	3	10.1016/j.ciresp.2022.01.013	36064171	WOS:000963755800001
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme	EUROPEAN JOURNAL OF CANCER	8,4	1	10.1016/j.ejca.2022.12.023	36706655	WOS:000931534200001
MET alterations in NSCLC-Current Perspectives and Future Challenges	JOURNAL OF THORACIC ONCOLOGY	20,4	D1	10.1016/j.jtho.2022.10.015	36441095	WOS:000973651100001
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations	JOURNAL OF THORACIC ONCOLOGY	20,4	D1	10.1016/j.jtho.2023.07.023	37541389	WOS:001104250800001
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry	JTO CLINICAL AND RESEARCH REPORTS			10.1016/j.jtocrr.2022.100433	36793384	WOS:001150083500001
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer	LUNG CANCER	5,3	2	10.1016/j.lungcan.2023.02.002	36812760	WOS:000992854100001
Immunogenicity of COVID-19 vaccines in lung cancer patients	LUNG CANCER	5,3	2	10.1016/j.lungcan.2023.107323	37639820	WOS:001067203900001
Q-TWIST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial	LUNG CANCER	5,3	2	10.1016/j.lungcan.2023.107376	37722340	WOS:001082089000001
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial	LANCET	168,9	D1	10.1016/S0140-6736(22)02420-5	36495879	WOS:000924006800001

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges	NATURE REVIEWS CLINICAL ONCOLOGY	78,8	D1	10.1038/s41571-023-00794-7	37488229	WOS:001034522900002
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	MELANOMA RESEARCH	2,2	3	10.1097/CMR.0000000000000888	36988401	WOS:001059482500005
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817	JOURNAL FOR IMMUNOTHERAPY OF CANCER	10,9	1	10.1136/jitc-2022-006127	36725084	WOS:000940883200001
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY	4,9	2	10.1177/17588359231157641	36895850	WOS:000943283400001
Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study	JOURNAL OF FOOT AND ANKLE RESEARCH	2,9	2	10.1186/s13047-023-00650-y	37599367	WOS:001051143400001
Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer	JCO CLINICAL CANCER INFORMATICS	4,2		10.1200/CCI.22.00062		WOS:001133302300003
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)	JOURNAL OF CLINICAL ONCOLOGY	45,4	D1	10.1200/JCO.22.02561	37603816	WOS:001081587100007
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers	JCO PRECISION ONCOLOGY	4,6	2	10.1200/PO.22.00546	36862967	WOS:001118469500005
Study of Ferroptosis Transmission by Small Extracellular Vesicles in Epithelial Ovarian Cancer Cells	ANTIOXIDANTS	7,0	D1	10.3390/antiox12010183	36671044	WOS:000916942200001
Wellbeing and Complementary Therapies in Breast Cancer Peripheral Neuropathy Care: A Scoping Review Focused on Foot Health	CANCERS	5,2	2	10.3390/cancers15072110	37046771	WOS:000969544800001
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study	CANCERS	5,2	2	10.3390/cancers15113030	37296992	WOS:001005367900001
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer	CANCERS	5,2	2	10.3390/cancers15174373	37686649	WOS:001061054600001
Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5,6	1	10.3390/ijms241310798	37445988	WOS:001031205700001
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort	JOURNAL OF CLINICAL MEDICINE	3,9	2	10.3390/jcm12010112	36614913	WOS:000910252900001
Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis	REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR	1,2	4	10.1016/j.remn.2022.07.003		WOS:001042789700001